| 000 | 01346 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250515214114.0 | ||
| 264 | 0 | _c20100629 | |
| 008 | 201006s 0 0 eng d | ||
| 022 | _a1936-2692 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFatodu, Hugh | |
| 245 | 0 | 0 |
_aEvolving regulatory landscape with erythropoiesis-stimulating agents and impact on managed care. _h[electronic resource] |
| 260 |
_bThe American journal of managed care _cMar 2010 |
||
| 300 |
_aS74-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_aAnemia _xdrug therapy |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xchemically induced |
| 650 | 0 | 4 | _aDrug and Narcotic Control |
| 650 | 0 | 4 | _aDrug-Related Side Effects and Adverse Reactions |
| 650 | 0 | 4 |
_aHematinics _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInsurance, Health, Reimbursement |
| 650 | 0 | 4 |
_aKidney Failure, Chronic _xcomplications |
| 650 | 0 | 4 | _aManaged Care Programs |
| 650 | 0 | 4 |
_aNeoplasms _xcomplications |
| 650 | 0 | 4 | _aProduct Surveillance, Postmarketing |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 |
_aStroke _xchemically induced |
| 650 | 0 | 4 |
_aUnited States _xepidemiology |
| 650 | 0 | 4 | _aUnited States Food and Drug Administration |
| 773 | 0 |
_tThe American journal of managed care _gvol. 16 Suppl Issues _gp. S74-9 |
|
| 999 |
_c19662503 _d19662503 |
||